Cart
sales@molnova.com
SCD1 inhibitor-3
CAS No. 1282606-48-7
SCD1 inhibitor-3( —— )
Catalog No. M35059 CAS No. 1282606-48-7
SCD1 inhibitor-3 (ML-270) is a highly effective and orally available compound that inhibits SCD1 with remarkable safety.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 128 | Get Quote |
|
| 5MG | 187 | Get Quote |
|
| 10MG | 297 | Get Quote |
|
| 25MG | 490 | Get Quote |
|
| 50MG | 707 | Get Quote |
|
| 100MG | 972 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSCD1 inhibitor-3
-
NoteResearch use only, not for human use.
-
Brief DescriptionSCD1 inhibitor-3 (ML-270) is a highly effective and orally available compound that inhibits SCD1 with remarkable safety.
-
DescriptionSCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer.
-
In Vitro——
-
In VivoSCD1 inhibitor-3 (compound 17a) (5 mg/kg; p.o.; 4 hours) reduces the plasma C16:1/C16:0 triglycerides desaturation index by 54 %.SCD1 inhibitor-3 (2~10 mg/kg; p.o.; 4 hours) makes a dose-responsive reduction of plasma triglycerides desaturation index.Animal Model:Lewis rats Dosage:5 mg/kg Administration:P.o.; 4 hours Result:Reduced the plasma C16:1/C16:0 triglycerides desaturation index by 54 %.Animal Model:Lewis rats Dosage:2~10 mg/kg Administration:P.o.; 4 hours Result:A dose-responsive reduction of plasma triglycerides desaturation index.
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetDehydrogenase
-
RecptorDehydrogenase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1282606-48-7
-
Formula Weight393.37
-
Molecular FormulaC19H16FN7O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 125 mg/mL (317.77 mM)
-
SMILESFc1ccc(Cn2ncn(-c3cc(n[nH]3)C(=O)NCc3cccnc3)c2=O)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sun S, et al. Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors. Bioorg Med Chem. 2015;23(3):455-465.?
molnova catalog
related products
-
Enoxolone
Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption.
-
PfDHODH-IN-1
PfDHODH-IN-1 is an inhibitor of Plasmodium falciparum dihydroorotate dehydrogenase(PfDHODH) which catalyzes the rate-limiting step for DNA and RNA biosynthesis. PfDHODH-IN-1 has antimalarial activity.
-
DHODH-IN-11
DHODH-IN-11 is a leflunomide derivative and weak dihydroorotate dehydrogenase (DHODH) inhibitor with a pKa of 5.03.A compound structurally related to leflunomide was designed, which contained furan ring (compound 14a).
